GVR Report cover Hormonal Contraceptive Market Size, Share & Trends Report

Hormonal Contraceptive Market Size, Share & Trends Analysis Report By Method (IUDs, Pills, Implants), By Hormone (Combination Hormonal Contraceptives, Progestin-only), By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-2-68038-348-5
  • Number of Report Pages: 100
  • Format: PDF, Horizon Databook
  • Historical Range: 2017 - 2021
  • Forecast Period: 2023 - 2030 
  • Industry: Healthcare

Report Overview

The global hormonal contraceptive market size was valued at USD 17.3 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.31% from 2023 to 2030. Increasing awareness in emerging economies regarding hormonal contraception methods, growing investments by the major players for the R&D of novel contraceptive devices, and supportive initiatives by various governments to increase access to contraceptive products are the factors propelling the industry’s growth. Rising awareness regarding the various options available to avoid pregnancy is expected to boost industry growth.

North America hormonal contraceptive market size and growth rate, 2023 - 2030 (USD Billion)

The key companies are collaborating with eminent personalities to make people aware of the contraceptives that aid in avoiding pregnancy. For instance, in July 2019, Allergen Plc partnered with Ashley Tisdale, a musician, and actress, for the awareness campaign “Women Who Know”. The campaign informs women about the various options available for contraception including Loestrin Fe, a hormonal pill by Allergen. Furthermore, the World Health Organization provided guidelines for the use of hormonal contraceptives, such as intrauterine devices, progestogen injectables, and implants, for women at greater risk of HIV.

The guidelines were provided based on the ECHO trial, which didn’t show any differences in the acquisition of HIV in the women using non-hormonal contraceptives, such as copper intrauterine devices, levonorgestrel implants, or DMPA-IM. Moreover, the rising investment in R&D and commercialization of new products are some of the key strategies adopted by the key players to increase their industry share. For instance, in April 2021, Mayne Pharma received U.S. FDA approval for NEXTSTELLIS and estetrol for avoiding pregnancy. It is the only contraceptive with E4, a plant-based estrogen having few potential benefits compared to other estrogens.


COVID-19 hormonal contraceptive market impact: 4.21% growth from 2020 to 2021

Pandemic Impact

Post-COVID Outlook

The pandemic had a significant impact on the industry owing to the decline in the number of family planning where hormonal contraceptives are mostly utilized. According to the United Nations Population Fund (UNFPA) and Avenir Health data, approximately 12 million women were unable to receive family planning services with around 1.4 million unplanned pregnancies in 2020

Despite some declines in 2020, many countries revived their family planning services, which resulted in increased sales of hormonal contraceptives. For instance, as per the UNFPA data, around 56% of the countries reported pre-COVID levels of family planning services

The pandemic also disrupted the supply chains and manufacturing of hormonal contraceptives, which affected the availability of the supplies and the resources for family planning. As per the article published in Gynecology & Obstetrics, in May 2020, the use of contraception dropped by 10% in the year owing to closed clinics, unavailable providers, or stock-outs

With the relaxation of the COVID-19 curbs, the industry is slowly stabilizing as the supply chain and manufacturing operations are normalizing. The companies are reviving their manufacturing facilities to fulfill the demand for hormonal contraceptives. For instance, in April 2020, Agile Therapeutics agreed with Corium for the manufacturing and supply of the Twirla, a transdermal contraceptive patch


Long-acting birth control methods, such as IUDs and vaginal rings, have become more popular in the last decade, and their adoption is on a rise. This can be attributed to the steady increase in copayment for oral contraceptive pills and subsequently, improving affordability. Major IUDs currently available in the U.S. are Kyleena, Mirena, Skyla, and Liletta. Moreover, adopting long-acting reversible devices is one of the major driving factors for industry growth. For instance, according to the study published in the Pharmaceutical Journal, long-acting reversible devices are one of the most successful contraception techniques as it eliminates human error, with failure rates of less than 1% in the 1st year of usage, as it does not require user input regularly.

Method Insights

Based on methods, the global industry has been further segmented into pills, Intrauterine Devices (IUDs), injectables, vaginal rings, implants, and patches. The contraceptive pills segment dominated the global industry in 2022 and accounted for the largest revenue share of more than 45.01% of the overall revenue. The segment growth can be attributed to the simple and easy administration, feasibly available products, increasing & greater awareness about the pills due to early market entry compared to long-acting reversible devices, and higher efficiency of around 99% in timely consumption.

Furthermore, the presence of various major players in the field and growing penetration in emerging countries are expected to contribute to segment growth. For instance, in July 2021, the MHRA approved the OTC sale of contraceptive pills in U.K. pharmacies. Two contraceptive pill brands, Hana and Lovima, are selling desogestrel- synthetic progesterone, OTC with a brief consultation with a pharmacist. The IUDs segment is expected to observe a significant CAGR during the forecast period due to the increasing adoption of long-acting methods of contraception. More than 99.0% effectivity, longer action span, no effect of the device on breastfeeding, and normal fertility after removal of the device are some factors attributing to the segment's growth.

Hormone Insights

Based on hormones, the global industry has been further bifurcated into combination hormonal contraceptives and progestin-only. The combination of hormonal contraceptives dominated the industry in 2021 and accounted for the largest share of the overall revenue. The segment is estimated to expand further at the second-fastest CAGR maintaining its leading position during the forecast period. The growth of the segment can be attributed to the lower risk of pregnancy as it blocks pregnancy by two different mechanisms leading to higher success rates. Moreover, these contraceptives are associated with a lower risk of developing acne as compared to progestin-only contraceptives.

Global hormonal contraceptives market share and size, 2022 (%)

The progestin-only contraceptives segment is expected to witness the fastest growth rate of more than 4.50% during the forecast period. This can be attributed to the no estrogen-related side effects, such as migraines and fluid retention, with the medications. Both these contraceptives are similar in effects and no other contraceptive methods are required when intended within 5 days of menstrual bleeding. According to the Centers for Disease Control & Prevention, out of 100, approximately 9 women become pregnant when these contraceptives are typically used.

Regional Insights

North America dominated the global industry in 2022 holding the largest revenue share 43.0%. It is expected to maintain its leading position growing at the fastest CAGR of more than 5.00% over the forecast period. This can be attributed to the existence of major players, increased sexual health awareness, and a high proportion of unwanted pregnancies. For instance, according to the American College of Obstetricians & Gynecologists, approximately 99% of sexually active women in the U.S. use contraception, and around 88% prefer to use reversible methods of contraception, such as IUDs, implants, vaginal rings, patches, and others.

Hormonal Contraceptive Market Trends by Region

The Asia Pacific region is projected to witness the second-fastest CAGR during the forecast period. A large pool target population, a rise in investment by key players, the introduction of novel contraception devices for females, and a rapidly growing economy are the major factors supplementing regional growth. A rising number of product launches, favorable government reimbursement policies, and increased sexual health awareness are anticipated to foster the Europe regional market. For instance, in May 2021, Pantarhei Bioscience received approval for the oral contraceptive Estelle from the European Commission. Estelle contains E4, a synthetic estrogen, which has been developed by Pantarhei in 2000.

Key Companies & Market Share Insights

The industry is fragmented due to the presence of several generic drugs. Approval & commercialization of various products, increasing geographical reach, and expanding application scope of already-existing products are the major strategies being adopted by industry participants to enhance their share. For instance, in June 2021, Teva Pharmaceuticals USA launched the generic form 0f NuvaRing, Ethinyl estradiol, and etonogestrel vaginal ring contraceptive. In February 2020, Agile Therapeutics, Inc. received U.S. FDA approval for the Twirla, a transdermal patch containing levonorgestrel and Ethinylestradiol. Some of the prominent players in the global hormonal contraceptive market include:

  • Abbvie Inc.

  • Afaxys, Inc.

  • Teva Pharmaceuticals Industries Ltd.

  • Bayer AG

  • Organon Group of Companies

  • Pfizer

  • Agile Therapeutics

  • Janssen Pharmaceuticals Inc.

  • Lupin Pharmaceuticals Inc.

  • Pregna International Ltd.

Hormonal Contraceptive Market Report Scope

Report Attribute


Market size value in 2023

USD 18.0 billion

Revenue forecast in 2030

USD 24.2 billion

Growth rate

CAGR of 4.31% from 2023 to 2030

Base year for estimation


Historical data

2017 - 2021

Forecast period

2023 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2023 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Hormone, method, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Australia; South Korea; Mexico; Brazil; Argentina; South Africa; Saudi Arabia; UAE

Key companies profiled

Abbvie, Inc.; Afaxys, Inc.; Teva Pharmaceuticals Industries Ltd.; Bayer AG; Merck & Co. Inc.; Organon Group of Companies; Pfizer; Agile Therapeutics; and Janssen Pharmaceuticals, Inc.; Lupin Pharmaceuticals Inc.; Pregna International Ltd.

Customization scope

Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Hormonal Contraceptive Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global hormonal contraceptive market report based on hormone, method, and region:

Global Hormonal Contraceptive Market Segmentation

  • Method Outlook (Revenue, USD Million, 2017 - 2030)

    • Pill

    • Intrauterine Device (IUD)

    • Injectable

    • Vaginal Ring

    • Implant

    • Patch

  • Hormone Outlook (Revenue, USD Million, 2017 - 2030)

    • Combination Hormonal Contraceptives

    • Progestin Only

  • Regional Outlook (Revenue, USD Million, 2017 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

    • Latin America

      • Mexico

      • Brazil

      • Argentina

    • Middle East & Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.